Patient Characteristics, Disease Burden, Treatment Patterns and Outcomes in Patients with Acromegaly: Real-World Evidence from the Malaysian Acromegaly Registry.

IF 0.6 Q4 ENDOCRINOLOGY & METABOLISM
Mohamed Badrulnizam Long Bidin, Abdul Mueed Khan, Florence Hui Sieng Tan, Nor Azizah Aziz, Norhaliza Mohd Ali, Nor Azmi Kamaruddin, Shireene Ratna Vethakkan, Balraj Sethi, Zanariah Hussein
{"title":"Patient Characteristics, Disease Burden, Treatment Patterns and Outcomes in Patients with Acromegaly: Real-World Evidence from the Malaysian Acromegaly Registry.","authors":"Mohamed Badrulnizam Long Bidin,&nbsp;Abdul Mueed Khan,&nbsp;Florence Hui Sieng Tan,&nbsp;Nor Azizah Aziz,&nbsp;Norhaliza Mohd Ali,&nbsp;Nor Azmi Kamaruddin,&nbsp;Shireene Ratna Vethakkan,&nbsp;Balraj Sethi,&nbsp;Zanariah Hussein","doi":"10.15605/jafes.038.01.06","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aims to report the demographic features of patients with acromegaly, the disease burden, and the corresponding treatment patterns and outcomes in Malaysia.</p><p><strong>Methodology: </strong>This is a retrospective study that included patients from the Malaysian Acromegaly registry who were diagnosed with acromegaly from 1970 onwards. Data collected included patient demographics, clinical manifestations of acromegaly, biochemical results and imaging findings. Information regarding treatment modalities and their outcomes was also obtained.</p><p><strong>Results: </strong>Registry data was collected from 2013 to 2016 and included 140 patients with acromegaly from 12 participating hospitals. Median disease duration was 5.5 years (range 1.0 - 41.0 years). Most patients had macroadenoma (67%), while 15% were diagnosed with microadenoma. Hypertension (49.3%), diabetes (37.1%) and hypopituitarism (27.9%) were the most common co-morbidities for patients with acromegaly. Majority of patients had surgical intervention as primary treatment (65.9%) while 20.7% were treated medically, mainly with dopamine agonists (18.5%). Most patients had inadequate disease control after first-line treatment regardless of treatment modality (79.4%).</p><p><strong>Conclusion: </strong>This registry study provides epidemiological data on patients with acromegaly in Malaysia and serves as an initial step for further population-based studies.</p>","PeriodicalId":41792,"journal":{"name":"Journal of the ASEAN Federation of Endocrine Societies","volume":"38 1","pages":"75-80"},"PeriodicalIF":0.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0c/64/JAFES-38-1-75.PMC10213168.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the ASEAN Federation of Endocrine Societies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15605/jafes.038.01.06","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study aims to report the demographic features of patients with acromegaly, the disease burden, and the corresponding treatment patterns and outcomes in Malaysia.

Methodology: This is a retrospective study that included patients from the Malaysian Acromegaly registry who were diagnosed with acromegaly from 1970 onwards. Data collected included patient demographics, clinical manifestations of acromegaly, biochemical results and imaging findings. Information regarding treatment modalities and their outcomes was also obtained.

Results: Registry data was collected from 2013 to 2016 and included 140 patients with acromegaly from 12 participating hospitals. Median disease duration was 5.5 years (range 1.0 - 41.0 years). Most patients had macroadenoma (67%), while 15% were diagnosed with microadenoma. Hypertension (49.3%), diabetes (37.1%) and hypopituitarism (27.9%) were the most common co-morbidities for patients with acromegaly. Majority of patients had surgical intervention as primary treatment (65.9%) while 20.7% were treated medically, mainly with dopamine agonists (18.5%). Most patients had inadequate disease control after first-line treatment regardless of treatment modality (79.4%).

Conclusion: This registry study provides epidemiological data on patients with acromegaly in Malaysia and serves as an initial step for further population-based studies.

肢端肥大症患者的特征、疾病负担、治疗模式和结果:来自马来西亚肢端肥大症登记处的真实世界证据。
目的:本研究旨在报告马来西亚肢端肥大症患者的人口统计学特征、疾病负担以及相应的治疗模式和结果。方法:这是一项回顾性研究,包括马来西亚肢端肥大症登记处1970年以来诊断为肢端肥大症的患者。收集的资料包括患者人口统计学、肢端肥大症的临床表现、生化结果和影像学表现。还获得了有关治疗方式及其结果的信息。结果:注册数据收集于2013年至2016年,包括来自12家参与医院的140例肢端肥大症患者。中位病程为5.5年(1.0 - 41.0年)。大多数患者为大腺瘤(67%),而15%诊断为微腺瘤。高血压(49.3%)、糖尿病(37.1%)和垂体功能低下(27.9%)是肢端肥大症患者最常见的合并症。大多数患者以手术干预为主要治疗方法(65.9%),20.7%的患者接受药物治疗,以多巴胺激动剂为主(18.5%)。无论何种治疗方式,大多数患者在一线治疗后疾病控制不足(79.4%)。结论:这项登记研究提供了马来西亚肢端肥大症患者的流行病学数据,并为进一步的基于人群的研究奠定了基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.20
自引率
0.00%
发文量
22
审稿时长
8 weeks
期刊介绍: The Journal of the ASEAN Federation of Endocrine Societies (JAFES) is an OPEN ACCESS, internationally peer-reviewed, English language, medical and health science journal that is published in print two times a year by the ASEAN Federation of Endocrine Societies. It shall serve as the endocrine window between the ASEAN region and the world, featuring original papers and publishing key findings from specialists and experts of endocrinology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信